Literature DB >> 19445550

Pain treatment with opioids : achieving the minimal effective and the minimal interacting dose.

Pierangelo Geppetti1, Silvia Benemei.   

Abstract

Appropriate and successful management of pain with opioid analgesics is based on tailoring pharmacologic treatment to the individual and identifying the minimal effective dose at which pain is controlled with minimal adverse effects. Morphine and morphine-like-agonists exhibit similar pharmacodynamic profiles, but substantially different receptor affinities and pharmacokinetic properties, which dictate the dosage, route and regimen required to achieve analgesic effect. Opioids exhibit differences in drug elimination resulting in marked variations in the plasma half-life value. Although fentanyl is more potent than morphine, with a shorter duration of action than parenteral morphine, its oral bioavailability is poor and it is administered transdermally. Morphine, with a short half-life and a time to steady-state plasma concentrations of 10-12 hours is better suited than transdermal fentanyl for initial opioid therapy and for the treatment of unstable pain, which requires a fluctuating opioid dose. International guidelines recommend normal-release morphine for initial optimization of individual dose because its pharmacokinetics allow 'real-time' dose regimen changes and rapid identification of the dose required for pain control. Once an effective normal-release morphine dosage is achieved, other administration routes, formulations and opioids can be considered as required. Despite guidelines advocating that transdermal fentanyl should only be used in patients who are shown to be tolerant to strong opioid therapy, in Italy and other European countries, controlled-release or transdermal opioids are often used when starting opioid therapy. Opioids are associated with a wide range of adverse reactions, but these can be minimized with careful drug titration and maintenance. A major challenge with pain control is polypharmacy and the risk of pharmacokinetic or pharmacodynamic drug-drug interactions. Prevention and management of interactions rely on careful and timely adjustment of drug regimens involved, according to the severity of the effect. Dose titration is the key to successful therapy initiation with strong opioids in patients with moderate-to-severe pain. It is the only way to establish the optimal and minimal effective dose and provides the best protection against adverse effects. Committed physicians should adhere to guidelines on the appropriate use of opioids in all patients, particularly those with a high risk of adverse reactions.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19445550     DOI: 10.2165/0044011-200929001-00002

Source DB:  PubMed          Journal:  Clin Drug Investig        ISSN: 1173-2563            Impact factor:   2.859


  45 in total

1.  Opioids in Italy: is marketing more powerful than the law?

Authors:  Alessandro Chinellato; Gianni Terrazzani; Tom Walley; Pietro Giusti
Journal:  Lancet       Date:  2003-07-05       Impact factor: 79.321

Review 2.  Contribution to variability in response to opioids.

Authors:  Geoffrey W Hanks; Colette Reid
Journal:  Support Care Cancer       Date:  2004-12-10       Impact factor: 3.603

3.  Plasma concentrations of morphine, morphine-6-glucuronide and morphine-3-glucuronide and their relationship with analgesia and side effects in patients with cancer-related pain.

Authors:  Columba Quigley; Simon Joel; Naina Patel; Amina Baksh; Maurice Slevin
Journal:  Palliat Med       Date:  2003-03       Impact factor: 4.762

4.  Standard therapy with opioids in chronic pain management : ORTIBER study.

Authors:  Antonio Gatti; Carlo Reale; Roberto Occhioni; Marta Luzi; Alessandra Canneti; Claudia De Polo; Martina Gubernari; Massimo Mammucari; Alessandro Fabrizio Sabato
Journal:  Clin Drug Investig       Date:  2009       Impact factor: 2.859

Review 5.  [Interactions between benzodiazepines and opioids].

Authors:  Bruno Megarbane; Papa Gueye; Frédéric Baud
Journal:  Ann Med Interne (Paris)       Date:  2003-11

6.  Opioid control of the release of calcitonin gene-related peptide-like material from the rat spinal cord in vivo.

Authors:  E Collin; D Frechilla; M Pohl; S Bourgoin; D Le Bars; M Hamon; F Cesselin
Journal:  Brain Res       Date:  1993-04-23       Impact factor: 3.252

Review 7.  Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metabolized drugs.

Authors:  Janyce F Rogers; Anne N Nafziger; Joseph S Bertino
Journal:  Am J Med       Date:  2002-12-15       Impact factor: 4.965

8.  Contribution of brainstem GABA(A) synaptic transmission to morphine analgesic tolerance.

Authors:  Junyi Ma; Zhizhong Z Pan
Journal:  Pain       Date:  2006-03-09       Impact factor: 6.961

Review 9.  Opioid reward mechanisms: a key role in drug abuse?

Authors:  A Herz
Journal:  Can J Physiol Pharmacol       Date:  1998-03       Impact factor: 2.273

Review 10.  Leukocyte-derived opioid peptides and inhibition of pain.

Authors:  Halina Machelska; Christoph Stein
Journal:  J Neuroimmune Pharmacol       Date:  2006-03       Impact factor: 7.285

View more
  11 in total

Review 1.  Opioid pharmaceuticals and addiction: the issues, and research directions seeking solutions.

Authors:  Wendy M Walwyn; Karen A Miotto; Christopher J Evans
Journal:  Drug Alcohol Depend       Date:  2010-02-25       Impact factor: 4.492

Review 2.  Oxycodone/paracetamol: a low-dose synergic combination useful in different types of pain.

Authors:  Antonio Gatti; Elisabetta Sabato; Anna Rita Di Paolo; Massimo Mammucari; Alessandro Fabrizio Sabato
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

3.  Time to pain relief after immediate-release morphine in episodic pain: the TIME study.

Authors:  Claudio Lo Presti; Alessandro Roscetti; Davide Muriess; Massimo Mammucari
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

4.  Effects of opioid rotation in chronic pain patients: ORTIBARN study.

Authors:  Antonio Gatti; Carlo Reale; Marta Luzi; Alessandra Canneti; Rocco Domenico Mediati; Renato Vellucci; Massimo Mammucari; Alessandro Fabrizio Sabato
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

Review 5.  Morphine/naltrexone.

Authors:  Sean T Duggan; Lesley J Scott
Journal:  CNS Drugs       Date:  2010-06       Impact factor: 5.749

Review 6.  Long-term Opioids Linked to Hypogonadism and the Role of Testosterone Supplementation Therapy.

Authors:  Suganya Marudhai; Mauli Patel; Sharathshiva Valaiyaduppu Subas; Mohammad R Ghani; Vishal Busa; Ahmed Dardeir; Ivan Cancarevic
Journal:  Cureus       Date:  2020-10-05

7.  A new real-time method for detecting the effect of fentanyl using the preoperative pressure pain threshold and Narcotrend index: a randomized study in female surgery patients.

Authors:  Guangyou Duan; Shanna Guo; Huiming Zhan; Dongmei Qi; Yuhao Zhang; Xianwei Zhang
Journal:  Medicine (Baltimore)       Date:  2015-01       Impact factor: 1.889

Review 8.  Guidelines for prescribing opioids for chronic non-cancer pain in Korea.

Authors:  Eung Don Kim; Jin Young Lee; Ji Seon Son; Gyeong Jo Byeon; Jin Seok Yeo; Do Wan Kim; Sie Hyeon Yoo; Ji Hee Hong; Hue Jung Park
Journal:  Korean J Pain       Date:  2016-12-30

9.  To predict sufentanil requirement for postoperative pain control using a real-time method: A prospective observational cohort study.

Authors:  Yuhao Zhang; Guangyou Duan; Shanna Guo; Ying Ying; Penghao Huang; Mi Zhang; Ningbo Li; Xianwei Zhang
Journal:  Medicine (Baltimore)       Date:  2016-06       Impact factor: 1.889

10.  Healthcare professionals' perceptions on the use of opioid analgesics for the treatment of cancer-related pain in Cyprus: A mixed-method study.

Authors:  Andreas Charalambous; Marios Zorpas; Constantina Cloconi; Yolanda Kading
Journal:  SAGE Open Med       Date:  2019-04-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.